Drug Type Small molecule drug |
Synonyms Dazostinag, CRD-5500, TAK676 |
Target |
Mechanism STING agonists(Stimulator of interferon genes agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H22F2N8O10P2S2 |
InChIKeySIIGKCBSQKWSLM-YYWHNGOBSA-N |
CAS Registry2553413-86-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | 22 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 22 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | JP | 22 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | AT | 22 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | BE | 22 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CA | 22 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | FR | 22 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | IL | 22 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | PL | 22 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | PR | 22 Jul 2020 |